摘要
目的探讨原发免疫性血小板减少症(ITP)患者外周血CD14+CD16+单核细胞数量的变化及其临床意义。方法采用流式细胞术检测ITP患者治疗前组(n=31)、治疗后缓解组(n=25)和健康对照组(n=30)受检者外周血CD14+CD16+单核细胞数量,采用ELISA方法检测血清TNF-α、IL-12和IL-10浓度,使用Sysmex XE-2100做血小板计数。结果 CD14+CD16+单核细胞(%):ITP患者治疗前组、治疗后缓解组与健康对照组分别为6.49±0.87vs 2.60±0.75 vs 1.10±0.58(P<0.01);TNF-α,IL-12和IL-10在3组之间的表达差异均有统计学意义(P<0.01),ITP患者治疗前组CD14+CD16+单核细胞比例与血小板计数,TNF-α和IL-10浓度具有相关(r=-0.623;r=0.492;r=-0.661,P<0.05)。结论 CD14+CD16+单核细胞数量在ITP患者中明显增高,并且与细胞因子的异常表达相关,提示CD14+CD16+单核细胞可能通过调控细胞因子的表达参与疾病的发生发展,为未来临床判断ITP的治疗效果提供了新的潜在标志物。
Objective To determine the expression of CD14 ＋ CD16 ＋ monocyte in peripheral blood from patients with primary immune thrombocytopenia （ITP） and explore its clinical significance. Methods Peripheral biood samples from ITP patients before treatment （ n = 31 ）, patients who achieved remissions after treatment （ n = 25） and healthy controls （ n = 30）were obtained. Expression of CD14＋ CD16＋ monocytes was determined using flow cytometry. The level of cytokines （TNF- a,IL-12,IL-10） was detected by ELISA. Platelet count was determined by Sysmex XE-2100. Results The percentages of CD14＋ CD16＋ monocyte expressions in the three groups were 6.49± 0. 87, 2. 60 ± 0.75,1.10±0.58, respectively. The expression of TNF-a, IL-12 and IL-10 between the three groups suggested statistically significant difference （P 〈 0. 001 ）. Moreover, CD14＋ CD16＋ monocyte expression was positively correlated with platelet count and serum TNF-a level（ r = - 0. 623 ; r = 0. 492 ,P 〈 0. 05 ）, and negatively correlated with serum IL-10 level（r = - 0. 661, P 〈 0. 01 ）. Conclusion The number of monocytes in CD14 ＋ CD16＋ is significantly higher in ITP patients and correlates with the abnormal expression of eytokines, suggesting that CD14＋ CD16 ＋ monocytes may be involved in the development of the disease by regulating cytokine expression, which might provide a new potential marker for clinical judgment of ITP in the future.
出处
《中国输血杂志》
CAS
北大核心
2015年第9期1081-1084,共4页
Chinese Journal of Blood Transfusion
基金
国家自然科学基金(81401358)
第二军医大学优秀硕士生苗子培育基金
长海医院"1255"学科建设计划(CH125531500)
